Depression Clinical Trials in Dallas

View 70 new treatments for depression near you in Dallas, TX. Every day, Power helps over 527 depression patients connect with leading medical research.

ALTO-300 for Depression

Alto Neuroscience Clinic, Plano + 18 more

This trial is testing ALTO-300, a new medication, to see if it can make antidepressants work better for patients who are already taking them.

Verified

Recruiting
Phase 2
Est. 3 - 6 Weeks
Adam Savitz, MD, PhD
Study Director

AXS-05 for Depression

Axsome Clinic, Dallas + 1 more

This trial is testing AXS-05, a new medication, to see if it can prevent depression from returning in people who have already improved with it. The study focuses on those with major depressive disorder and aims to maintain their balanced brain chemicals to keep them feeling better. AXS-05 (a combination of dextromethorphan and bupropion) has shown positive results in previous trials for major depressive disorder.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

Multiple Medications for Bipolar Depression

Research Clinic, Dallas + 1 more

This trial is testing four different medications to find the best treatment for adults with bipolar disorder type 1 who are currently depressed. The medications work by balancing brain chemicals that affect mood. The goal is to help patients recover from depression and stay well.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

Hydrocortisone for Memory Impairment

Research Clinic, Dallas + 1 more

Chronic corticosteroid (CS) exposure is associated with changes in memory and the hippocampus in both humans and in animal models. The hippocampus has a high concentration of glucocorticoid receptors (GCRs), and the pre-clinical literature demonstrates shortening of apical dendrites in the CA3 region of the hippocampus and decreased neurogenesis in the dentate gyrus (DG) following CS administration. In humans, both stress and CS exposure are associated with a decline in declarative memory performance (a process mediated by the hippocampus). Impairment in declarative memory and hippocampal atrophy are reported in patients with excessive CS release due to Cushing's disease, and, by our group, in patients receiving prescription CS therapy. These findings have important implications for patients with mood disorders, as a large subset of people with major depressive disorder (MDD) show evidence of HPA axis activation, elevated cortisol and, importantly, resistance to the effects of CSs on both the HPA axis and on declarative memory. Thus, resistance to corticosteroids appears to be a consequence of MDD. this study will examine changes in declarative memory, as well as use state-of-the-art high-resolution multimodal neuroimaging, including structural and functional (i.e., task-based and resting state) MRI, in both men and women healthy controls, and, as an exploratory aim, a depressed group, given 3-day exposures to hydrocortisone (160 mg/day) or placebo. The study will translate preclinical findings to humans, provide valuable data on possible sex differences in the response to cortisol and, for the first time, identify specific hippocampal subfields (e.g., CA3/DG) in humans that are most sensitive to acute CS effects. Using resting state fMRI data and whole brain connectomics using graph theoretical approaches, we will determine the effects of cortisol exposure on functional brain networks. Furthermore, this will be the first study to use neuroimaging to compare the brain's response to CSs in people with depression vs. controls, and determine whether depressed people demonstrate glucocorticoid resistance within the hippocampus. We hypothesize that hippocampal response to acute CSs will be greatest in the CA3/DG subfield, greater in women than in men, and that depressed people will show a blunted hippocampal response to CSs compared to controls. A multidisciplinary research team with extensive experience in CS effects on the brain and hippocampal subfield neuroimaging, and a prior history of research collaboration, will conduct the project.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Sherwood Brown, MD, PhD
Principal Investigator

Seltorexant for Depression

Janssen Clinic, Fort Worth + 1 more

This trial is testing seltorexant to see if it can help people with depression and insomnia who haven't improved with their current antidepressants. Seltorexant aims to improve mood and sleep by acting on certain brain receptors.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Janssen Research & Development, LLC Clinical Trail
Study Director

REL-1017 for Depression

Relmada Clinic, Dallas + 4 more

This trial tests if adding REL-1017 to current antidepressant treatments can better help people with Major Depressive Disorder. Participants will take their usual antidepressants plus either REL-1017 or another substance. The goal is to see if REL-1017 can improve their depression symptoms. REL-1017 (esmethadone) has shown potential rapid and sustained antidepressant effects in previous trials.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Marco Pappagallo, MD
Study Director

Psilocybin for Depression

Research Clinic, Plano + 1 more

This trial is testing psilocybin, a substance from mushrooms, to see if it can help adults with depression who may not respond well to current treatments. Psilocybin works by affecting brain chemicals related to mood. Psilocybin has shown promise as a treatment for major depressive disorder and was designated as a breakthrough therapy by the FDA in 2019.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Cariprazine for Bipolar Disorder in Youth

AbbVie Clinic, Plano + 2 more

This trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
ALLERGAN INC.
Study Director

Ketamine vs Midazolam for Suicidal Thoughts

Research Clinic, Dallas + 1 more

This project aims to examine the efficacy of ketamine, a rapidly acting medication shown to decrease suicidality in adults in as short as hours or days, as opposed to weeks. The study design is a double-blind, randomized, active-control trial of adolescents (ages 13-18 years) with recent suicidal behaviors (suicide attempt or increased suicidal ideation). All participants must be receiving standard of care treatment which may range broadly from both outpatient and inpatient programs which include clinically indicated psychosocial and/or psychopharmacological treatments. Ketamine/midazolam treatment will occur twice weekly during the first two weeks of the study, followed by weekly assessments through week 12.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
Madhukar Trivedi, MD
Principal Investigator

Aticaprant for Major Depressive Disorder

Janssen Clinic, Fort Worth + 2 more

This trial is testing aticaprant to see if it can help people with major depressive disorder who still feel very down and don't enjoy things despite taking other antidepressants. The study focuses on adults who haven't responded well to their current treatments. Aticaprant works by blocking a specific brain receptor, which might help improve their mood and reduce depressive symptoms.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Page 1 of 5

Frequently Asked Questions

How much do depression clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do depression clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across depression trials in New York City, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for depression patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

How many people will have already taken the drug in my study?

This depends on the phase of the trial, as well as the condition. For drugs that are in Phase 3, it's typical that at least 200 many patients will have participated over the first and second phases. For Phase 2, 100 is the typical number of people who will have participated.

Where in New York City is research being conducted?

Manhattan is the most active borough in New York City for clinical trials in depression, with neighborhoods such as the Upper East Side and Midtown hosting major research centers. The top individual hospitals include Memorial Sloan Kettering Cancer Center, Columbia University Medical Center, Icahn School of Medicine at Mount Sinai, and NYU Langone Health, which collectively run the majority of depression clinical trials in the city.

What promising new drugs are being tested?

Many of the drugs being researched near New York City work via glutamate: the main excitatory signal in the brain. Some of these drugs shift how your natural glutamate functions and others, like ketamine, block one of the receptors that glutamate works on. The other common category of drugs being explored are psychedelics, like psilocybin, which are thought to work by helping your brain become more plastic. Other drugs being researched in multiple trials include Aticaprant and BHV-7000.

What non-medication treatments are being researched?

Non-drug treatments for depression being researched in clinical trials in New York City can be categorized into psychotherapy, digital and mobile app-based interventions, brain stimulation techniques like TMS, and educational and training programs. These trials include approaches like Cognitive Behavioral Therapy, mindfulness, family support, symptom education, and neurofeedback.

Why are others applying to these studies?

  • I have tried two other drugs that didn't have any positive affect on my mental health and am hoping that trying out this trial will help me find a solution.

    M.A. Patient

    Depression Patient

  • I've tried many anti-depressants in my 45 year struggle with Major Depression. I'm hoping this study is the 'game changer'

    B.E. Patient

    Late-Life Depression Patient

  • I've tried more then 5 drugs for depression and it's very depressing frustrating when they do not work, or even help nothing, I'm still looking for that one or 2 that will help

    A.L. Patient

    Major Depression Patient